丁香园Insight数据库援引国家药品监督管理局药品审评中心数据显示,11月1日~11月15日,中心共承办460例申报进度,其中受理化药申请328项,中药申请31项,抗体类29项,血液制品相关18项,多肽13项,非抗体类蛋白9项,疫苗类8项,诊断试剂4项,细胞治疗4项,微生物相关3项,基因治疗1项。回顾11月上半月,共有一类新药临床申请数量30个,抗肿瘤药物仍是主要研发方向。《每日经济新闻》记者...
Source Link丁香园Insight数据库援引国家药品监督管理局药品审评中心数据显示,11月1日~11月15日,中心共承办460例申报进度,其中受理化药申请328项,中药申请31项,抗体类29项,血液制品相关18项,多肽13项,非抗体类蛋白9项,疫苗类8项,诊断试剂4项,细胞治疗4项,微生物相关3项,基因治疗1项。回顾11月上半月,共有一类新药临床申请数量30个,抗肿瘤药物仍是主要研发方向。《每日经济新闻》记者...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.